UY33993A - Análogo macrocíclico de la sangliferina y su método de producción - Google Patents

Análogo macrocíclico de la sangliferina y su método de producción

Info

Publication number
UY33993A
UY33993A UY0001033993A UY33993A UY33993A UY 33993 A UY33993 A UY 33993A UY 0001033993 A UY0001033993 A UY 0001033993A UY 33993 A UY33993 A UY 33993A UY 33993 A UY33993 A UY 33993A
Authority
UY
Uruguay
Prior art keywords
sangliferina
production method
macrocyclic
analog
macrocyclic analog
Prior art date
Application number
UY0001033993A
Other languages
English (en)
Inventor
Gregory Matthew Alan
Moss Steven James
Wilkinson Barrie
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of UY33993A publication Critical patent/UY33993A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se suministra, entre otros, un compuesto de la Fórmula 1, para su empleo en el tratamiento de infecciones virales o a modo de inmunosupresor.
UY0001033993A 2011-03-29 2012-03-29 Análogo macrocíclico de la sangliferina y su método de producción UY33993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production

Publications (1)

Publication Number Publication Date
UY33993A true UY33993A (es) 2012-10-31

Family

ID=46001313

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033993A UY33993A (es) 2011-03-29 2012-03-29 Análogo macrocíclico de la sangliferina y su método de producción

Country Status (29)

Country Link
US (2) US9090657B2 (es)
EP (2) EP2691413B1 (es)
JP (2) JP6118793B2 (es)
KR (2) KR101911484B1 (es)
CN (3) CN103619869B (es)
AR (1) AR085724A1 (es)
AU (2) AU2012235880B2 (es)
BR (2) BR112013024974A2 (es)
CA (2) CA2830831C (es)
CL (2) CL2013002739A1 (es)
CY (2) CY1116318T1 (es)
DK (2) DK2691412T3 (es)
EA (2) EA023848B1 (es)
ES (2) ES2533437T3 (es)
HK (2) HK1189236A1 (es)
HR (2) HRP20150184T1 (es)
IL (2) IL228509B (es)
JO (1) JO3063B1 (es)
MX (2) MX345351B (es)
MY (2) MY170637A (es)
PL (2) PL2691413T3 (es)
PT (2) PT2691412E (es)
RS (2) RS53964B1 (es)
SG (2) SG193568A1 (es)
SI (2) SI2691413T1 (es)
TW (1) TWI525098B (es)
UY (1) UY33993A (es)
WO (2) WO2012131371A1 (es)
ZA (2) ZA201307149B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
BR112019009903A2 (pt) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
WO2008084368A2 (en) 2007-01-04 2008-07-17 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
ES2556211T3 (es) 2008-09-24 2016-01-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Agrupación de genes novedosa
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
BR112012019866A8 (pt) * 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JP6086869B2 (ja) * 2010-12-20 2017-03-08 ネウロビベ プハルマセウトイカル エービー サングリフェリン誘導体及びそれらの製造方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
PL2691413T3 (pl) 2015-05-29
BR112013024965A2 (pt) 2017-04-18
US9139613B2 (en) 2015-09-22
AR085724A1 (es) 2013-10-23
IL228509A0 (en) 2013-12-31
CN103635484A (zh) 2014-03-12
AU2012235961B2 (en) 2016-09-01
CY1116186T1 (el) 2017-02-08
CN103635484B (zh) 2017-05-10
KR20140057481A (ko) 2014-05-13
MY170618A (en) 2019-08-21
PT2691412E (pt) 2015-03-25
JO3063B1 (ar) 2017-03-15
WO2012131371A1 (en) 2012-10-04
EA023907B1 (ru) 2016-07-29
EA201391399A1 (ru) 2014-02-28
CA2830827C (en) 2020-03-10
MX345352B (es) 2017-01-26
IL228509B (en) 2018-02-28
SG193568A1 (en) 2013-11-29
AU2012235880B2 (en) 2016-11-17
DK2691412T3 (en) 2015-04-07
ES2533437T3 (es) 2015-04-10
TW201300398A (zh) 2013-01-01
KR20140071958A (ko) 2014-06-12
AU2012235880A1 (en) 2013-10-17
HK1189237A1 (en) 2014-05-30
SI2691412T1 (sl) 2015-05-29
BR112013024974A2 (pt) 2016-09-06
IL228508A0 (en) 2013-12-31
KR101868084B1 (ko) 2018-06-18
EP2691413A1 (en) 2014-02-05
EP2691412B1 (en) 2014-12-24
AU2012235961A1 (en) 2013-10-10
CL2013002739A1 (es) 2014-07-11
PT2691413E (pt) 2015-03-25
CN103619869A (zh) 2014-03-05
CN103619869B (zh) 2015-11-25
HRP20150187T1 (en) 2015-06-05
CA2830827A1 (en) 2012-10-04
MX2013011043A (es) 2014-04-25
CN107417766A (zh) 2017-12-01
US9090657B2 (en) 2015-07-28
CY1116318T1 (el) 2017-02-08
RS53963B1 (en) 2015-08-31
JP2014514290A (ja) 2014-06-19
MX2013011051A (es) 2014-03-13
PL2691412T3 (pl) 2015-08-31
JP2014510746A (ja) 2014-05-01
EP2691413B1 (en) 2014-12-24
MX345351B (es) 2017-01-26
TWI525098B (zh) 2016-03-11
US20140038885A1 (en) 2014-02-06
JP6118792B2 (ja) 2017-04-26
CA2830831A1 (en) 2012-10-04
HK1189236A1 (en) 2014-05-30
ZA201307149B (en) 2015-04-29
US20120251581A1 (en) 2012-10-04
RS53964B1 (en) 2015-08-31
SG193569A1 (en) 2013-11-29
JP6118793B2 (ja) 2017-04-26
ES2533438T3 (es) 2015-04-10
CA2830831C (en) 2020-03-10
HRP20150184T1 (hr) 2015-05-08
ZA201307231B (en) 2015-05-27
EA201391396A1 (ru) 2014-02-28
CL2013002740A1 (es) 2014-07-11
IL228508B (en) 2018-01-31
MY170637A (en) 2019-08-21
DK2691413T3 (en) 2015-04-07
SI2691413T1 (sl) 2015-05-29
WO2012131377A1 (en) 2012-10-04
EA023848B1 (ru) 2016-07-29
KR101911484B1 (ko) 2018-10-24
EP2691412A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
UY33993A (es) Análogo macrocíclico de la sangliferina y su método de producción
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
AR089993A1 (es) Macrociclos peptidomimeticos
PE20160841A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
EA201691194A1 (ru) Стимуляторы ргц
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CO6351786A2 (es) Inkibidores de la cinasa map p38
UY33467A (es) Compuestos pyrazolo[1,5-a]pirimidinas para tratamiento antiviral del virus sincicial respiratorio humano, sus composiciones y métodos de producción.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
PH12016501699A1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
ECSP11011258A (es) Pirimidinas fusionadas
CR20130515A (es) Imidazopiridazinas como inhibidores de quinasa akt
SV2016005301A (es) Nuevos compuestos macrocíclicos
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
SG10201900541QA (en) Derivatives of xanthone compounds
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
PH12015500399A1 (en) Azaindolines

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210804